Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Bryan Johnson's Blueprint & Testosterone

Longevity entrepreneur

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (educational content)

Reference only. Not medical advice.

What can go wrong

Critics (Matt Kaeberlein, Morgan Levine) note the n=1 design can't separate signal from noise and that commercial epigenetic 'age' claims are not validated. The protocol is essentially non-replicable (cost, medical team), and Johnson sells the very protocol he promotes.

This is something to take to a clinician. The Atlas can tell you what is known about bryan johnson's blueprint & testosterone in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Bryan Johnson (who sold Braintree/Venmo to PayPal) runs 'Blueprint,' a heavily measured, ~$2M/year self-experiment, and sells the protocol as products (Blueprint Stack, supplements; 'Blueprint Basics' ~$333/month). He posts hormone panels and, as of 2025, reported total testosterone ~735 ng/dL with intact LH/FSH (cited as evidence he is not on TRT), though he previously used testosterone (Androderm) to offset aggressive caloric restriction, then tapered off. Notably his protocol works partly against high T (caloric restriction lowers it); he optimizes for a longevity-oriented profile.

An n=1 longevity protocol that optimizes for a 'youthful' hormone profile, not max T.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Longevity-optimized protocol; supplements sold as products

What people get wrong

  • Often saidBlueprint's thousands of studies prove the stack works

    ActuallyThose are studies of individual components; the only trial of the full stack had one subject (Johnson). He has a direct financial stake in the products.

Who profits, and who pushes back

  • Bryan Johnson

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itlarge following

    Founder/owner of Blueprint products, direct equity and revenue. Testosterone figures are self-reported.

At a glance

Protocol
Blueprint (~$2M/yr self-experiment)
Sells
Blueprint products (~$333/mo Basics)
T (2025)
~735 ng/dL, intact LH/FSH (self-reported)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Bryan Johnson's Blueprint & Testosterone. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.